WO2002036767A3 - Therapeutic oligonucleotides of reduced toxicity - Google Patents
Therapeutic oligonucleotides of reduced toxicity Download PDFInfo
- Publication number
- WO2002036767A3 WO2002036767A3 PCT/CA2001/001540 CA0101540W WO0236767A3 WO 2002036767 A3 WO2002036767 A3 WO 2002036767A3 CA 0101540 W CA0101540 W CA 0101540W WO 0236767 A3 WO0236767 A3 WO 0236767A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- therapeutic oligonucleotide
- oligonucleotides
- aggregates
- reduced toxicity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01983356A EP1330520A2 (en) | 2000-11-02 | 2001-10-31 | Therapeutic oligonucleotides of reduced toxicity |
CA002426047A CA2426047A1 (en) | 2000-11-02 | 2001-10-31 | Therapeutic oligonucleotides of reduced toxicity |
AU2002214868A AU2002214868A1 (en) | 2000-11-02 | 2001-10-31 | Therapeutic oligonucleotides of reduced toxicity |
JP2002539513A JP2004512383A (en) | 2000-11-02 | 2001-10-31 | Therapeutic oligonucleotides with reduced toxicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24517600P | 2000-11-02 | 2000-11-02 | |
US60/245,176 | 2000-11-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002036767A2 WO2002036767A2 (en) | 2002-05-10 |
WO2002036767A3 true WO2002036767A3 (en) | 2003-01-23 |
Family
ID=22925600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2001/001540 WO2002036767A2 (en) | 2000-11-02 | 2001-10-31 | Therapeutic oligonucleotides of reduced toxicity |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1330520A2 (en) |
JP (1) | JP2004512383A (en) |
AU (1) | AU2002214868A1 (en) |
CA (1) | CA2426047A1 (en) |
WO (1) | WO2002036767A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US8258106B2 (en) | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ616745A (en) * | 2008-07-18 | 2014-06-27 | Oncogenex Tech Inc | Antisense formulation |
WO2010062697A2 (en) | 2008-10-30 | 2010-06-03 | Peixuan Guo | Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses |
WO2023282344A1 (en) * | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | Nephrotoxicity reducing agent |
TW202337473A (en) * | 2021-07-08 | 2023-10-01 | 日商日本新藥股份有限公司 | Nephrotoxicity-reducing agent |
CA3225573A1 (en) * | 2021-07-08 | 2023-01-12 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006827A1 (en) * | 1995-08-14 | 1997-02-27 | Icn Pharmaceuticals | Control of cd44 gene expression for therapeutic use |
-
2001
- 2001-10-31 JP JP2002539513A patent/JP2004512383A/en active Pending
- 2001-10-31 WO PCT/CA2001/001540 patent/WO2002036767A2/en not_active Application Discontinuation
- 2001-10-31 EP EP01983356A patent/EP1330520A2/en not_active Withdrawn
- 2001-10-31 CA CA002426047A patent/CA2426047A1/en not_active Abandoned
- 2001-10-31 AU AU2002214868A patent/AU2002214868A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006827A1 (en) * | 1995-08-14 | 1997-02-27 | Icn Pharmaceuticals | Control of cd44 gene expression for therapeutic use |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8258106B2 (en) | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
Also Published As
Publication number | Publication date |
---|---|
EP1330520A2 (en) | 2003-07-30 |
CA2426047A1 (en) | 2002-05-10 |
AU2002214868A1 (en) | 2002-05-15 |
JP2004512383A (en) | 2004-04-22 |
WO2002036767A2 (en) | 2002-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003013437A3 (en) | Compositions and methods for the prevention and treatment of huntington's disease | |
WO2005049630A3 (en) | Antisense modulation of kinesin-like 1 expression | |
WO2004100881A3 (en) | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | |
DE60207744D1 (en) | PROCESS FOR THE PREPARATION OF 1,5,6,7-TETRAHYDROPYRROLO [3,2-C] DERIVATIVES FOR THE TREATMENT OF FATIBILITY | |
WO2003011887A3 (en) | Antisense modulation of apolipoprotein b expression | |
EP1478322A4 (en) | Beta-2'-OR 3'-HALONUCLEOSIDES | |
HK1048990A1 (en) | Novel compounds. | |
ZA979961B (en) | 5-HT1F agonists | |
WO2003070283A3 (en) | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent | |
TW200633986A (en) | Therapeutic agents | |
WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
WO2002036767A3 (en) | Therapeutic oligonucleotides of reduced toxicity | |
WO2009027978A8 (en) | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS | |
WO2004073375A8 (en) | Podophyllotoxin derivatives as antitumor agents | |
WO2006066154A3 (en) | Casein kinase 2 antisense therapy | |
WO2003050244A3 (en) | Antisense modulation of g protein-coupled receptor etbr-lp-2 expression | |
EP1248633A4 (en) | Antisense modulation of glycogen synthase kinase 3 beta expression | |
EP0916670A3 (en) | Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists | |
WO2003030826A3 (en) | Antisense modulation of insulin-like growth factor binding protein 5 expression | |
WO2003099224A3 (en) | Antisense moodulation of kinesin-like 1 expression | |
WO2003057847A3 (en) | METHODS AND MATERIALS FOR MODULATING ENaC-BETA | |
WO2005039480A8 (en) | AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT | |
MXPA05009428A (en) | Compositions and methods for preventing and treating endotoxin-related diseases and conditions. | |
EP1173458A4 (en) | Antisense modulation of sra expression | |
EP1448762A4 (en) | Antisense modulation of toll-like receptor 4 expression field of the invention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2426047 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002539513 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001983356 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001983356 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001983356 Country of ref document: EP |